[A23-01] Lutetium vipivotide tetraxetan (prostate cancer) – Benefit assessment according to §35a Social Code Book V
Last updated 06.07.2023
Project no.:
A23-01
Commission:
Commission awarded on 10.01.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
In combination with androgen deprivation therapy with or without androgen receptor pathway inhibition for the treatment of adult patients with progressive prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy
- Patients for whom abiraterone in combination with prednisone or prednisolone, enzalutamide or best supportive care is the most appropriate therapy for the individual patient: hint of a non-quantifiable added benefit
- Patients for whom cabazitaxel or olaparib is the most appropriate therapy for the individual patient: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A23-46 | Lutetium vipivotide tetraxetan (prostate cancer) – Addendum to Commission A23-01 | Commission completed |
Federal Joint Committee (G-BA)
2023-07-06 A G-BA decision was published.